Trial Profile
A Phase I study of ET-743 in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 03 Aug 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
- 14 Jun 2016 New trial record
- 04 Apr 2016 Status changed from not yet recruiting to recruiting.